Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
February 08 2022 - 8:00AM
Esperion (NASDAQ: ESPR), today announced it will report fourth
quarter and full year 2021 financial results before the open of the
U.S. financial markets on Tuesday, February 22, 2022.
Following the release, company management will host a webcast
and conference call at 8:00 a.m. ET to discuss financial results
and business progress. The call can be accessed by dialing (877)
831-3840 (domestic) or (253) 237-1184 (international) five minutes
prior to the start of the call and providing the access code
7349619.
A live audio webcast can be accessed on the investor and media
section of the Esperion website at investor.esperion.com. Access to
the webcast replay will be available approximately two hours after
completion of the call and will be archived on the Company's
website for approximately 90 days.
ESPERION Therapeutics
Esperion works hard to make our medicines easy to get, easy to
take and easy to have. We discover, develop and commercialize
innovative medicines and combinations to lower cholesterol,
especially for patients whose needs aren’t being met by the status
quo. Our entrepreneurial team of industry leaders is inclusive,
passionate and resourceful. We are singularly focused on managing
cholesterol so you can improve your health easily. Esperion
commercializes NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic
acid and ezetimibe) Tablets and is the leader in the development of
convenient oral, once-daily non-statin LDL-cholesterol lowering
drugs for patients with high levels of bad cholesterol. For more
information, please visit www.esperion.com and follow us on Twitter
at www.twitter.com/EsperionInc.
Investor Contact:Kaitlyn
BroscoEsperioncorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024